Novartis | NVS - Assets


Novartis reported $118.53B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bausch Health Companies USD 24.79B 296M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Canopy Growth CAD 1.12B 12.54M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Drreddys Laboratories INR 579.35B 573.08B Mar/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
J&J USD 201.06B 167M Jun/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Pacira USD 1.24B 35.44M Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Phibro Animal Health USD 1.45B 39.56M Mar/2026
Prestige Brands USD 4.57B 1.07B Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026
Zoetis USD 15.15B 313M Mar/2026